Published 20 January 2009, doi:10.1136/bmj.b217
Cite this as: BMJ 2009;338:b217

News

Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine

Zosia Kmietowicz

1 London

The first 150 words of the full text of this article appear below.

The drug giant Eli Lilly has agreed to pay $1.4bn (£1bn; {euro}1.1bn) in settlement for the marketing of its antipsychotic drug olanzapine (Zyprexa) for off-label uses. It is the largest individual corporate fine in history.

The drug, which is licensed for the treatment of schizophrenia and bipolar disorder, was widely promoted by Eli Lilly between September 1999 and November 2003 to treat more common disorders, such as dementia, agitation, aggression, depression, and sleep problems, said the US Department of Justice in a statement.

The company began its promotion by encouraging doctors who treated people in nursing homes and assisted care facilities to prescribe olanzapine, because one of the drug’s side effects is sedation. It claimed that "this side effect was a therapeutic benefit, not an adverse event." The sales force used the slogan "5 at 5," meaning that 5 mg of olanzapine at 5 pm would help patients sleep, said . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Rapid Responses:

Read all Rapid Responses

Need for caution
Santhana K Gunasekaran
bmj.com, 23 Jan 2009 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ